[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338329-105":59,"doc-detail-338329-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-egfr-exon-20-insertion-mutations-in-non-small-cell-lung-cancer-changes-in-treatment-strategies-are-coming","Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer - Changes in Treatment Strategies are Coming","","Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent the third most frequent EGFR alteration in non-small cell lung cancer (NSCLC), occurring in about 4%-12% of EGFR-positive cases. These mutations show substantial molecular subtype diversity and contribute to an inferior prognosis due to limited sensitivity to immunotherapy, chemotherapy, and conventional targeted therapy. Amivantamab and sunvozertinib have shown meaningful first-line activity, and additional targeted agents and resistance mechanisms are being actively explored. This review consolidates epidemiology, molecular features, detection approaches, and recent therapeutic advances for EGFR ex20ins NSCLC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-egfr-exon-20-insertion-mutations-in-non-small-cell-lung-cancer-changes-in-treatment-strategies-are-coming/338329/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-egfr-exon-20-insertion-mutations-in-non-small-cell-lung-cancer-changes-in-treatment-strategies-are-coming/338329.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the clinical relevance of EGFR exon 20 insertion (ex20ins) mutations in NSCLC?","Question",{"text":112,"@type":113},"EGFR ex20ins mutations occur in roughly 4%-12% of EGFR-positive NSCLC and are associated with notable heterogeneity and an inferior prognosis compared with classical EGFR mutations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do patients with EGFR ex20ins mutations have limited treatment options?",{"text":117,"@type":113},"They often show insensitivity to conventional approaches such as immunotherapy, chemotherapy, and existing targeted therapies, leading to unmet medical need for more effective treatments.",{"name":119,"@type":110,"acceptedAnswer":120},"Which treatments have shown notable first-line efficacy for EGFR ex20ins NSCLC?",{"text":121,"@type":113},"Amivantamab and sunvozertinib have demonstrated notable efficacy as first-line treatments, and other emerging targeted drugs are also being investigated.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338329,1790194581,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":14,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming  \nHaoli Liu, MSc 1 􀀁, Jing Qin, MD2, and Xinyu Qian, MD3  \nCancer Control Volume 31: 1–16  \n© The Author(s) 2024  \nArticle reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748241292782](DOI: 10.1177/10732748241292782)[ ](DOI: 10.1177/10732748241292782)[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nAbstract  \nEpidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are the third most frequent EGFR mutation type, following only exon 19 deletions and exon 21 L858R point mutations. EGFR ex20ins mutations are found in approximately 4%-12% of all EGFR-positive non-small cell lung cancers (NSCLCs) . Unlike classical EGFR mutations, EGFR ex20ins mutations display remarkable subtype diversity and heterogeneity. Patients harboring these mutations generally have an inferior prognosis because of insensitivity to conventional treatment approaches such as immunotherapy, chemotherapy, and targeted therapy. Consequently, there remains a signiﬁcant unmet medical need for efﬁcacious treatments. Recently, amivantamab and sunvozertinib have demonstrated notable efﬁcacy as ﬁrst-line treatments, and several other promising novel targeted drugs are also challenging the status quo of traditional ﬁrst-line platinum-based chemotherapy regimens. These developments are anticipated to further improve survival outcomes for NSCLC patients with EGFR ex20ins mutations. Hence, this review summarizes the epidemiology, molecular attributes, detection methodologies, and therapeutic advancements for EGFR ex20ins mutations in NSCLC, and brieﬂy discusses the mechanisms of drug resistance.  \nKeywords  \nnon-small cell lung cancer, EGFR exon 20 insertion mutation inhibitor, molecular subtypes, detection, targeted treatment strategy  \nReceived June 28, 2024. Received revised September 10, 2024. Accepted for publication October 3, 2024.  \nIntroduction  \nAmong all cancers, lung cancer is the most frequently diagnosed malignancies and has one of the highest morbidity and mortality rates globally. GLOBOCAN 2020 statistics revealed that there were more than 2.2 million new lung cancer cases and 1 . 8 million new deaths worldwide.1 Non-small cell lung cancer (NSCLC) accounts for approximately 80%-85% of all lung cancers.2 Two decades ago, a pivotal discovery was made—epidermal growth factor receptor (EGFR) kinase domain mutations were observed in NSCLC, this ﬁnding subsequently fueled the development of EGFR tyrosine kinase inhibitors (TKIs) . This groundbreaking advancement significantly improved survival for affected patients. Currently, EGFR mutations are recognized as one of the most common mutation classes in NSCLC patients,3-5 with a prevalence  \nranging from 40% to 50% in Asian patients and 10% to 30% in Caucasian patients.6,7 The majority of these mutations occur  \n1 Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China  \n2Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China  \n3Department of Oncology, Hangzhou Cancer Hospital, Hangzhou First People’s Hospital, Hangzhou, China  \nCorresponding Author:  \nXinyu Qian, Department of Oncology, Hangzhou Cancer Hospita, Hangzhou First People’s Hospital, No.34 Yanguan Street Zhongshan Road (South) Shangchen District, Hangzhou 310022, China.  \nEmail: [qianxinyu@hospital.westlake.edu.cn](qianxinyu@hospital.westlake.edu.cn)  \nData Availability Statement included at the end of the article  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use","cbCaik1SBSFp8Z5R","https://ap.wps.com/l/cbCaik1SBSFp8Z5R","pdf",785632,16,"English","# Abstract\n# Keywords\n# Introduction\n## Epidemiology and clinical background\n## EGFR mutation classes and ex20ins characteristics","[{\"question\":\"What is the clinical relevance of EGFR exon 20 insertion (ex20ins) mutations in NSCLC?\",\"answer\":\"EGFR ex20ins mutations occur in roughly 4%-12% of EGFR-positive NSCLC and are associated with notable heterogeneity and an inferior prognosis compared with classical EGFR mutations.\"},{\"question\":\"Why do patients with EGFR ex20ins mutations have limited treatment options?\",\"answer\":\"They often show insensitivity to conventional approaches such as immunotherapy, chemotherapy, and existing targeted therapies, leading to unmet medical need for more effective treatments.\"},{\"question\":\"Which treatments have shown notable first-line efficacy for EGFR ex20ins NSCLC?\",\"answer\":\"Amivantamab and sunvozertinib have demonstrated notable efficacy as first-line treatments, and other emerging targeted drugs are also being investigated.\"}]","Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer - Changes in Treatment Strategies are Coming | PDF",1790023083,[146,150],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/d9e3374bd730a851b0c21505d3c5d19c.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/47e3be0a2d28812a9927d21f1c387231.webp",982,1270]